InSysBio to take part in JuliaCon 2026

events
Conference
June 24, 2026

InSysBio announces its participation in JuliaCon Global 2026 (Conference on the Julia programming language) which is to be held from August 10-15, 2026 at Johannes Gutenberg University Mainz, Germany. Ivan Borisov, Senior Software Developer, InSysBio, and Evgeny Metelkin, Technology Director, InSysBio, will give a talk:

August 12, 12:00–12:15 (Europe/Berlin), Room 4:

Ivan comments on the talk, "Virtual Populations (VPops) are widely used in Quantitative Systems Pharmacology (QSP) to represent variability in patient responses to therapy using parameterized dynamical models. Unlike traditional modeling approaches that focus on average treatment effects, VPop methods aim to reproduce the full distribution of clinical outcomes observed in trials.

We introduce VPopMIP, a Julia package implementing a Mixed-Integer Programming (MIP) formulation for generating VPops that match clinical endpoints. In contrast to many existing approaches that require individual-level patient data, VPopMIP enables calibration to published clinical summary statistics (e.g., response rates, medians, and confidence intervals), which are more commonly available in practice.

The method formulates virtual patient selection as a constrained optimization problem that enforces agreement with multiple outcome measures across therapies.

We demonstrate the methodology using a solid tumor model with multiple efficacy endpoints across treatment regimens. The results illustrate how MIP-based selection provides an efficient way to construct clinically consistent virtual populations".

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com

October 2022
MoTuWeThFrSaSu
     
1
2
3
4
5
6
7
8
9
10
11
12
1. 12 Oct 2022 16:07 InSysBio to take part in ACoP13 InSysBio announces its participation in the Thirteenth American Conference on Pharmacometrics (ACoP13) which is to be held in person from October 30th to November 2nd, 2022, at the Gaylord Rockies Resort & Convention Center in Aurora, Colorado. InSysBio team is going to present 7 posters in frames of the Conference
13
14
15
16
17
18
19
20
21
22
23
24
25
1. 25 Oct 2022 14:41 InSysBio to present its ePoster at ECTRIMS 2022 InSysBio team is going to present its poster in frames of 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis which is to be held October 26-28, Amsterdam, the Netherlands. The ePoster is going to be presented in frames of "Pathology and pathogenesis of MS - Neurodegeneration" ePoster Area, October 26
26
27
28
29
30
31
      
Upcoming Events
10.08
InSysBio to take part in JuliaCon 2026
Tags
Latest News
10.06
16th InSysBio’s Annual Internal Scientific Meeting
28.01
InSysBio to announce a new collaborative project with BeOne Medicines
29.10
InSysBio to announce its collaboration with BeOne Medicines
16.10
InSysBio to introduce a new data annotation service available in CYTOCON DB and fIVE DB
19.08
InSysBio to publish the new article "Revolutionizing drug discovery: Integrating artificial intelligence with quantitative systems pharmacology"